David Rosen, partner and co-chair of the Life Sciences Industry Team of Foley & Lardner LLP will participate in the Food and Drug Law Institute’s (FDLI) Annual Conference at the Bethesda North Marriott Hotel & Conference Center, April 12-13 in Bethesda, Md.
Mr. Rosen will be moderating a panel entitled, “Everything You’ve Always Wanted to Know About Marketed Unapproved Drugs* (*But Were Afraid to Ask).” Topics will include history of the Food and Drug Administration (FDA) and companies that market drug products without FDA approval, as well as where the FDA is heading with respect to its Compliance Policy Guide, enforcement activities and incentives.
The annual conference is a joint venture of the FDA and FDLI. This year’s program will focus on the impact of fast paced scientific breakthroughs which are driving technological innovations for healthier lives. The conference will explore the effects of these breakthroughs from a multitude of perspectives, on regulatory and reimbursement systems, government and industry, and most importantly, the people who are demanding access to such innovations for longer, healthier lives.
